NeuroVive Pharmaceutical: NeuroVive Share Upgraded to OTC Markets Group - OTCQX Best Market in the US
BusinessWire - Thu Jun 02, 6:15AM CDT
Regulatory News:
Neurovive Pharmaceutical: NeuroVive's R&D Team to Present Research Progress at Mitochondrial Medicine Conference
BusinessWire - Thu Apr 28, 2:14AM CDT
NeuroVive Pharmaceutical AB (STO:NVP) (publ), the pioneers in mitochondrial medicine, will present important research findings together with researchers at Lund University in three scientific poster presentations at the conference entitled "Mitochondrial Medicine: Developing New Treatments for Mitochondrial Disease" being held 4-6 May 2016 in Cambridge, United Kingdom.
NeuroVive Pharmaceutical: NeuroVive Starts Preclinical TBI Program in Collaboration with PENN
BusinessWire - Tue Apr 26, 8:38AM CDT
Regulatory News:
NeuroVive Pharmaceutical: NeuroVive Strengthens Its Organization with the Recruitment of Cecilia Hofvander as IR and Communications Director
BusinessWire - Mon Apr 11, 1:42AM CDT
Regulatory News:
Neurovive Pharmaceutical: NeuroVive announces the CiPRICS study enrols 100 patients and reports favourable safety evaluation
BusinessWire - Mon Mar 14, 2:42AM CDT
Regulatory News:
NeuroVive Announces Departure of CEO and Appointment of Jan Nilsson as Interim CEO
BusinessWire - Tue Sep 01, 7:06AM CDT
Regulatory News:
Neurovive Pharmaceutical: NeuroVive Share Upgraded on OTC Market in US
BusinessWire - Fri Jun 26, 10:28AM CDT
Regulatory News:
Neurovive Pharmaceutical: Neurovive Reports Topline Results of Phase III CIRCUS Study in Acute Myocardial Infarction
BusinessWire - Mon Jun 01, 1:47AM CDT
Regulatory News:
NeuroVive Asia Signs Collaboration Agreement with Sanofi for the Development and Commercialization of Ciclomulsion(R) in South Korea
BusinessWire - Tue May 26, 3:30AM CDT
Regulatory News:
Neurovive Pharmaceutical: Topline Result of Phase III Study of Ciclomulsion(R) in Acute Myocardial Infarction Expected This Quarter
BusinessWire - Mon May 25, 1:43AM CDT
Regulatory News:
Neurovive Pharmaceutical: NeuroVive: Interim report 1 Jan. 2015 till 31 Mar. 2015
BusinessWire - Wed May 20, 1:54AM CDT
Regulatory News:
Global Ischemic Stroke Pipeline Report 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w6cj3m/ischemic_stroke) has announced the addition of the "Ischemic Stroke - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemic Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemic Stroke and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science - Acorda Therapeutics, Inc. - Acticor Biotech - advanceCor GmbH - AGY Therapeutics, Inc. - Angion Biomedica Corp. - AstraZeneca PLC - Athersys, Inc. - Biogen Idec Inc. - BioTime, Inc. - D-Pharm Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Digna Biotech, S.L. - Genervon Biopharmaceuticals, LLC - GlaxoSmithKline plc - International Stem Cell Corporation - Laboratoires Pierre Fabre SA - Lumosa Therapeutics Co., Ltd. - MediaPharma s.r.l. - Mesoblast Limited - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neurotec Pharma SL - NeuroVive Pharmaceutical AB - Panacea Pharmaceuticals, Inc. - Pharmicell Co., Ltd. - PhytoHealth Corporation - SanBio, Inc. - Saneron CCEL Therapeutics, Inc. - Simcere Pharmaceutical Group - Stemedica Cell Technologies, Inc. - Vicore Pharma AB - Virogenomics, Inc. For more information visit http://www.researchandmarkets.com/research/w6...mic_stroke
BIIB: 287.04 (-0.31), ACOR: 25.91 (-0.14), GSK: 44.16 (+0.12), AZN: 30.91 (-0.24), ATHX: 2.17 (+0.02), CUR: 0.25 (unch)
NeuroVive Pharmaceutical: NeuroVive Completes Share Issue Raising SEK 70 Million for the Preparation of CicloMulsion(R)'s Clinical Trial in the US and Commercialization in Europe
BusinessWire - Fri May 08, 1:33AM CDT
Regulatory News:
NeuroVive Announces the Intention to Raise Additional Capital Through a Private Placement
BusinessWire - Thu May 07, 10:50AM CDT
Regulatory News:
Neurovive Pharmaceutical: Clinical Phase II Study with NeuroSTAT(R) for Traumatic Brain Injury Passes Safety Evaluation
BusinessWire - Tue Apr 21, 3:06AM CDT
Regulatory News:
Neurovive Pharmaceutical: NeuroVive establishes subsidiary in Lyon and extends collaboration with HCL
BusinessWire - Mon Apr 20, 1:41AM CDT
Regulatory News:
NeuroVive Pharmaceutical: Development of NVP014 for the Treatment of Stroke Enters New Phase in Collaboration with Isomerase Therapeutics
BusinessWire - Fri Apr 17, 1:40AM CDT
Regulatory News:
NeuroVive Pharmaceutical reports change in number of shares and votes
M2 - Wed Apr 01, 3:06AM CDT
NeuroVive Pharmaceutical AB (STO:NVP), a mitochondrial medicine company, announced on Tuesday that the number of shares and votes of the company, registered with the Swedish Companies Registration Office, has increased by 1,300,000.
OnCore Biopharma and Tekmira Pharmaceuticals Files for Merger - Releases Further Details about License Agreement With NeuroVive
BusinessWire - Thu Feb 05, 2:28AM CST
Regulatory News:
TKMR: 10.83 (+0.58)